{"id":441842,"date":"2021-02-23T08:18:14","date_gmt":"2021-02-23T13:18:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=441842"},"modified":"2021-02-23T08:18:14","modified_gmt":"2021-02-23T13:18:14","slug":"silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/","title":{"rendered":"Silo Pharma to Present at Proactive’s One2One Virtual Investor Forum"},"content":{"rendered":"
\n

Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders, announced today that Eric Weisblum, Chief Executive Officer will be presenting at Proactive’s One2One Virtual Investor Forum on Tuesday, February 23, at 1 p.m. EST.<\/p>\n

The Virtual One2One Investor Forum invitation will be sent to Proactive’s estimated 20,000 YouTube subscribers and will be broadcasted internationally.<\/p>\n

Mr. Weisblum\u2019s presentation will be followed by a Q&A session and it will be published online.<\/p>\n

For more information or to register for this event please visit https:\/\/www.proactiveinvestors.com.au\/register\/event_details\/322<\/u><\/a><\/p>\n

About Silo Pharma<\/p>\n

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders. Silo\u2019s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com .<\/p>\n

Safe Harbor and Forward-Looking Statements<\/p>\n

This news release contains “forward-looking statements” within the meaning of the \u201csafe-harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (\u201cSilo\u201d or \u201cthe Company\u201d) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n

Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders, announced today that Eric Weisblum, Chief Executive Officer will be presenting at Proactive’s One2One Virtual Investor Forum on Tuesday, February 23, at 1 p.m. EST. The Virtual One2One Investor Forum invitation will be sent to Proactive’s estimated 20,000 YouTube subscribers and will be broadcasted internationally. Mr. Weisblum\u2019s presentation will be followed by a Q&A session and it will be published online. For more information or to register for this event please visit https:\/\/www.proactiveinvestors.com.au\/register\/event_details\/322 About Silo Pharma Silo Pharma … <\/p>\n

Continue reading “Silo Pharma to Present at Proactive’s One2One Virtual Investor Forum”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-441842","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSilo Pharma to Present at Proactive's One2One Virtual Investor Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma to Present at Proactive's One2One Virtual Investor Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders, announced today that Eric Weisblum, Chief Executive Officer will be presenting at Proactive’s One2One Virtual Investor Forum on Tuesday, February 23, at 1 p.m. EST. The Virtual One2One Investor Forum invitation will be sent to Proactive’s estimated 20,000 YouTube subscribers and will be broadcasted internationally. Mr. Weisblum\u2019s presentation will be followed by a Q&A session and it will be published online. For more information or to register for this event please visit https:\/\/www.proactiveinvestors.com.au\/register\/event_details\/322 About Silo Pharma Silo Pharma … Continue reading "Silo Pharma to Present at Proactive’s One2One Virtual Investor Forum"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-23T13:18:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma to Present at Proactive’s One2One Virtual Investor Forum\",\"datePublished\":\"2021-02-23T13:18:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/\"},\"wordCount\":428,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/\",\"name\":\"Silo Pharma to Present at Proactive's One2One Virtual Investor Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ==\",\"datePublished\":\"2021-02-23T13:18:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma to Present at Proactive’s One2One Virtual Investor Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma to Present at Proactive's One2One Virtual Investor Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma to Present at Proactive's One2One Virtual Investor Forum - Market Newsdesk","og_description":"Englewood Cliffs, NJ, Feb. 23, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders, announced today that Eric Weisblum, Chief Executive Officer will be presenting at Proactive’s One2One Virtual Investor Forum on Tuesday, February 23, at 1 p.m. EST. The Virtual One2One Investor Forum invitation will be sent to Proactive’s estimated 20,000 YouTube subscribers and will be broadcasted internationally. Mr. Weisblum\u2019s presentation will be followed by a Q&A session and it will be published online. For more information or to register for this event please visit https:\/\/www.proactiveinvestors.com.au\/register\/event_details\/322 About Silo Pharma Silo Pharma … Continue reading \"Silo Pharma to Present at Proactive’s One2One Virtual Investor Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-23T13:18:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma to Present at Proactive’s One2One Virtual Investor Forum","datePublished":"2021-02-23T13:18:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/"},"wordCount":428,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/","name":"Silo Pharma to Present at Proactive's One2One Virtual Investor Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ==","datePublished":"2021-02-23T13:18:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE1Nzk4OSMzOTkwNjcwIzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-to-present-at-proactives-one2one-virtual-investor-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma to Present at Proactive’s One2One Virtual Investor Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=441842"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441842\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=441842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=441842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=441842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}